We are presenting three cases of iatrogenic Cushing syndrome in infants,
that we came across recently.
The first infant was an 8 month old boy, who was
brought to the outpatient for complaints of poor growth and hirsutism.
On initial history, the parents categorically denied administration of
any medication/‘tonic’ to the baby. However, when confronted again,
after a thorough investigative work-up that failed to reveal any
etiology, the mother admitted that she had been giving betamethasone
drops to the baby since the age of 1 month, when it was prescribed by a
local practioner for upper respiratory tract infection. She was so
impressed by the voracious appetite and mood elevation that she
continued it till the age of 7 months, and then stopped abruptly as she
herself sensed that the baby’s poor growth/ hirsuitism could be an
adverse effect.
The second infant was a 3-month-old boy who was
taking betamethasone drops for the last 2 ˝ months, again prescribed for
some minor respiratory tract illness. In this child the medication was
suddenly stopped during a period of stress (child had fever and lethargy
for 2 days). This precipitated an adrenal crisis (shock with severe
metabolic acidosis, hyperkalemia and hypoglycemia). Child was admitted
in the ICU and required stress doses of steroids and other supportive
care. He gradually improved and was later discharged on tapering doses
of oral steroids.
The third infant was an 8-month boy, who was
diagnosed with congenital glaucoma at the age of 3 months. He underwent
trabeculectomy at 6 months of age, and was prescribed betamethasone eye
drops to prevent post operative inflammation and subconjuctival fibrosis
[1]. At presentation (8-months age) the child had cushingoid habitus,
hirsutism and poor weight and height growth. His serum cortisol
estimation was low (1.19 mcg/dl), consistent with exogenous steroid
overdose.
In the first two cases reported here, glucocorticoids
were prescribed without any indication and then continued for
inappropriately long durations by the parents, leading to Cushing
syndrome. These cases illustrate how things can go awry if there is lack
of clear communication between the health caregiver and the patient’s
family regarding the dose, duration and adverse effects of medication.
Easy availability of almost all medications over the counter, as well as
medical practice by unqualified persons, predispose to such adverse
events. Strong measures are needed to curb non-prescription dispensing
by chemists, and practicing of medicine by quacks, who often prescribe
steroids as a quick-fix remedy for dubious indications. There is no
definitive indication for use of betamethasone oral drops in clinical
practice. The policy-makers and the pharmaceutical companies should
consider withdrawing this drug from the market.
In the third case, Cushing syndrome occurred
secondary to topical therapy with steroid eye drops. This is an
exceptional event and only four case reports are cited to date in
pediatric age [2-5]. This case highlights the fact that small but
tangible risk associated with topical steroid therapy should always be
kept in mind and all patients on steroids (systemic or topical) should
be closely monitored.
In all the three cases parents were explained
regarding the need for stress dosing of steroids during any illness for
the next 6 months. This is because the suppressed
hypothalamic–pituitary-adrenal axis takes time to recover its normal
function.
1. Nguyen KD, Lee DA. Effect of steroids and
nonsteroidal anti-inflammatory agents on human ocular fibroblast. Invest
Ophthalmol Vis Sci. 1992;33:2693-2701.
2. Ozerdem U, Levi L, Cheng L, Song MK, Scher C,
Freeman WR. Systemic toxicity of topical and periocular corticosteroid
therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol.
2000;107:240-1.
3. Steelman J, Kappy M. Adrenal suppression and
growth retardation from ocular corticosteroids. J Pediatr Ophthalmol
Strabismus. 2001;38:177-8.
4. Messina MF, Valenzise M, Aversa S, Arrigo T, Luca
FD. Iatrogenic Cushing syndrome caused by ocular glucocorticoids in a
child. BMJ Case Reports 2009; Published 1 January 2009; published online
8 May 2009.
5. Romano PE, Traisman HS, Green OC. Fluorinated corticosteroid
toxicity in infants. Am J Ophthalmol. 1977;84:249-50.